BHCM
LXRX icon

Boulder Hill Capital Management’s Lexicon Pharmaceuticals LXRX Stock Holding History

Boulder Hill Capital Management’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-256,400
Closed -$615K – 53
2024
Q1 		$615K Buy
+256,400
New +$551K 0.25% 82

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Boulder Hill Capital Management's LXRX Position: Q2 2024 in Review

Boulder Hill Capital Management sold out of Lexicon Pharmaceuticals (LXRX) in Q2 2024, closing a stake of 256,400 shares — an estimated $615K sold.

Boulder Hill Capital Management first reported a position in LXRX in Q1 2024 and held it in 1 quarter. The position peaked at $615K in Q1 2024. 127 funds tracked by Wall St. Rank hold LXRX as of Q2 2024.

  • Boulder Hill Capital Management reported no remaining Lexicon Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Boulder Hill Capital Management sold 256,400 Lexicon Pharmaceuticals shares in Q2 2024, an estimated $615K.
  • Boulder Hill Capital Management first reported a position in Lexicon Pharmaceuticals in Q1 2024 and held it in 1 quarter.
  • Boulder Hill Capital Management's Lexicon Pharmaceuticals position peaked at $615K in Q1 2024.
  • 127 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q2 2024.

Based on Boulder Hill Capital Management's 13F filing for Q2 2024.